Abstract
Insulin secretion and insulin sensitivity are impaired in Type 2 diabetes. Metformin improves insulin sensitivity by inhibiting hepatic glucose release. It is the preferred drug for first-line treatment in Type 2 diabetes. Sitagliptin, the first marketed dipeptidyl peptidase-IV inhibitor, improves insulin and glucagon secretions of the pancreatic β- and α-cells, respectively, in a strictly glucose-dependent manner by raising endogenous active glucagon-like peptide-1 concentrations. The combination of metformin and sitagliptin thus offers a beneficial and complementary addition of important drug actions on insulin resistance and insulin secretion. Metformin and sitagliptin are also available as a fixed-dose combination. This article reviews the published clinical studies on both substances and their combination, and evaluates the potential benefit of the metformin plus sitagliptin combination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.